Journals / Turkish Journal of Chemistry / 2018 / Cilt: 42 - Sayı: 2

Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents

Pages
482–492
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Compounds 2, 3, and 7 acted as inhibitors with IC50 values in the range of 84.08–165.38 µM for carbonic anhydrase isoenzyme I (hCA I), and compounds 3 and 4 demonstrated inhibitory effects against carbonic anhydrase isoenzyme II (hCA II) with IC50 values of 108.11 and 112.52 µM, respectively. hCA II was activated by derivatives 1, 2, 6, and 7 with AC50 values in the range of 85.53–146.59 µM.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this research, a new series of (E) -3-(4-substitutedphenyl)-1-(4’-morpholinophenyl)prop-2-en-1-one derivatives 1–7 was synthesized, aiming to develop effective antiproliferative agents.
📊
Key Findings & Data:The antiproliferative activities of compounds 1–7 were examined against HeLa and C6 cell lines at eight different concentrations using the BrdU ELISA assay.
💡
Conclusion & Impact:Compounds 2, 3, and 7 acted as inhibitors with IC50 values in the range of 84.08–165.38 µM for carbonic anhydrase isoenzyme I (hCA I), and compounds 3 and 4 demonstrated inhibitory effects against carbonic anhydrase isoenzyme II (hCA II) with IC50 values of 108.11 and 112.52 µM, respectively. hCA II was activated by derivatives 1, 2, 6, and 7 with AC50 values in the range of 85.53–146.59 µM.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this research, a new series of (E) -3-(4-substitutedphenyl)-1-(4’-morpholinophenyl)prop-2-en-1-one derivatives 1–7 was synthesized, aiming to develop effective antiproliferative agents. The antiproliferative activities of compounds 1–7 were examined against HeLa and C6 cell lines at eight different concentrations using the BrdU ELISA assay. The activity results were compared with reference anticancer drug 5-fluorouracil (5-FU). Compound 1 had almost the same antiproliferative activity as 5-FU. Compounds 1–7 were found to have greater effects against the C6 cell line than the HeLa cell line. These compounds were also tested in order to determine their effects on enzyme activities. Compounds 2 and 3 exhibited strong activator characteristics against pyruvate kinase isoenzyme M2 (PKM2) with AC 50 values of 2.2 and 14.28 µM. Compounds 2, 3, and 7 acted as inhibitors with IC50 values in the range of 84.08–165.38 µM for carbonic anhydrase isoenzyme I (hCA I), and compounds 3 and 4 demonstrated inhibitory effects against carbonic anhydrase isoenzyme II (hCA II) with IC50 values of 108.11 and 112.52 µM, respectively. hCA II was activated by derivatives 1, 2, 6, and 7 with AC50 values in the range of 85.53–146.59 µM.

🔖

Cite This Article

ADEM, Ş., YAĞLIOĞLU, A. Ş., DEMİRTAŞ, İ., GüLER, Ç., EMRE, E. E. O., İYİDOĞAN, A. K., AKTAR, B. S. K. (2022). Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents. Turkish Journal of Chemistry, Cilt: 42 - Sayı: 2, 482–492. https://ajindex.com/articles/602038

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (24)

  1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Int. J. Cancer 2015, 136, 359-386
  2. Shah, A.; Khan, A. M.; Qureshi, R.; Ansari, F. L.; Nazar, M. F.; Shah, S. S. Int. J. Mol. Sci. 2008, 9, 1424-1434
  3. Yadav, N.; Dixit, S. K.; Bhattacharya, A.; Mishra, L. C.; Sharma, M.; Awasthi, S. K.; Bhasin, V. K. Chem. Biol. Drug. Des. 2012, 80, 340-347
  4. Bano, S.; Javed, K.; Ahmad, S.; Rathish, I. G.; Singh, S.; Chaitanya, M.; Arunasree, K. M.; Alam, M. S. Eur. J. Med. Chem. 2013, 65, 51-59
  5. Bandgar, B. P.; Gawande, S. S.; Bodade, R. G.; Totre, J. V.; Khobragade, C. N. Bioorg. Med. Chem. 2010, 18, 1364-1370
  6. Sharma, H.; Patil, S.; Sanchez, T. W.; Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Bioorg. Med. Chem. 2011, 19, 2030-2045
  7. Mizuno, C. S.; Paul, S.; Suh, N.; Rimando, A. M. Bioorg. Med. Chem. Lett. 2010, 20, 7385-7387
  8. Pizzuti, L.; Piovesan, L. A.; Flores, A. F. C.; Quina, F. H.; Pereira, C. M. P. Ultrason. Sonochem. 2009, 16, 728-731
  9. Amir, M.; Javed, S. A.; Kumar, H. Med. Chem. Res. 2010, 199, 299-310
  10. Thanh, N. D.; Thanh Mai, N. T. Carbohydr. Res. 2009, 344, 2399-2405
  11. El Gaby, M. S. A.; Saleh, N. M.; Micky, J. A.; Ammar, Y. A.; Mohamed, H. S. A. Phosphorus Sulfur Silicon Relat. Elem. 2006, 181, 1655-1663
  12. Thirunarayan, G.; Renuka, V. J. Chil. Chem. Soc. 2014, 59, 2574-2581
  13. Zangade, S. B.; Jadhav, J. D.; Lalpod, Vibhute, Y. B.; Dawane, B. S. J. Chem. Pharml. Res. 2010, 2, 310-314
  14. Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.; Forman, D.; Bray, F. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No
  15. Lyon, France: International Agency for Research on Cancer, 2013
  16. Gey, G. Cancer Res. 1952, 12, 264-265
  17. Landry, J. J.; Pyl, P. T.; Rausch, T.; Zichner, T.; Tekkedil, M. M.; St¨utz, A. M.; Jauch, A.; Aiyar, R. S.; Pau, G.; Delhomme, N. G3-Genes Genom. Genet. 2013, 3, 1213-1224
  18. Karmakar, S; Olive, M. F; Banik, N. L. Neurochem Res. 2007, 32, 2235-2242
  19. Assadian, S; Aliaga, A; Del Maestro, R. F. Neuro-Oncology 2008, 10, 292-299
  20. Valable, S; Lemasson, B; Farion, R. NMR Biomed. 2008, 21, 1043-1056
  21. Valable, S; Barbier, E. L; Bernaudin, M. NeuroImage 2008, 40, 973-983
  22. Locasale, J. W.; Cantley, L. C. BMC Biol. 2010, 8, 88-90
  23. Vander Heiden, M. G. Nat. Rev. Drug. Discov. 2011, 10, 671-684
  24. Hamanaka, R. B.; Chandel, N. S. J. Exp. Med. 2012,